Literature DB >> 25722294

Immunogenicity of the Bivalent Oral Cholera Vaccine Shanchol in Haitian Adults With HIV Infection.

Louise C Ivers1, Richelle C Charles2, Isabelle J Hilaire3, Leslie M Mayo-Smith4, Jessica E Teng5, J Gregory Jerome3, Jenna Rychert4, Regina C LaRocque2, Peng Xu6, Pavol Kovácˇ6, Edward T Ryan2, Firdausi Qadri7, Charles P Almazor3, Molly F Franke8, Jason B Harris9.   

Abstract

We evaluated immune responses following bivalent oral cholera vaccination (Shanchol [Shantha Biotechnics]; BivWC) in a cohort of 25 human immunodeficiency virus (HIV)-infected adults in Haiti. Compared with adults without HIV infection, vaccination in HIV-infected individuals resulted in lower vibriocidal responses against Vibrio cholerae O1, and there was a positive relationship between the CD4(+) T-cell count and vibriocidal responses following vaccination. Nevertheless, seroconversion occurred at a rate of 65% against the Ogawa serotype and 74% against the Inaba serotype in adults with HIV infection. These results suggest that the vaccine retains substantial immunogenicity in adults with HIV infection and may benefit this population by protecting against cholera.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Cholera vaccine; HIV; Shanchol (BivWC); immunogenicity

Mesh：

Substances：

Year:  2015        PMID： 25722294      PMCID： PMC4539903          DOI： 10.1093/infdis/jiv108

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  11 in total

1.  Effectiveness of mass oral cholera vaccination in Beira, Mozambique.

Authors:  Marcelino E S Lucas; Jacqueline L Deen; Lorenz von Seidlein; Xuan-Yi Wang; Julia Ampuero; Mahesh Puri; Mohammad Ali; M Ansaruzzaman; Juvenaldo Amos; Arminda Macuamule; Philippe Cavailler; Philippe J Guerin; Claude Mahoudeau; Pierre Kahozi-Sangwa; Claire-Lise Chaignat; Avertino Barreto; Francisco F Songane; John D Clemens
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

2.  Immune responses to O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 Ogawa in adult Bangladeshi recipients of an oral killed cholera vaccine and comparison to responses in patients with cholera.

Authors:  Taher Uddin; Amena Aktar; Peng Xu; Russell A Johnson; M Arifur Rahman; Daniel T Leung; Sadia Afrin; Aklima Akter; Mohammad Murshid Alam; Atiqur Rahman; Fahima Chowdhury; Ashraful I Khan; Taufiqur Rahman Bhuiyan; Meagan K Bufano; Rasheduzzaman Rashu; Yanan Yu; Ying Wu-Freeman; Jason B Harris; Regina C LaRocque; Richelle C Charles; Pavol Kováč; Stephen B Calderwood; Edward T Ryan; Firdausi Qadri
Journal:  Am J Trop Med Hyg       Date:  2014-03-31       Impact factor: 2.345

3.  A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.

Authors:  R T Perry; C V Plowe; B Koumaré; F Bougoudogo; K L Kotloff; G A Losonsky; S S Wasserman; M M Levine
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

4.  Is HIV infection associated with an increased risk for cholera? Findings from a case-control study in Mozambique.

Authors:  Lorenz von Seidlein; Xuan-Yi Wang; Arminda Macuamule; Catarina Mondlane; Mahesh Puri; Ilse Hendriksen; Jacqueline L Deen; Claire-Lise Chaignat; John D Clemens; M Ansaruzzaman; Avertino Barreto; Francisco F Songane; Marcelino Lucas
Journal:  Trop Med Int Health       Date:  2008-03-06       Impact factor: 2.622

5.  Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh.

Authors:  Debasish Saha; Regina C LaRocque; Ashraful I Khan; Jason B Harris; Yasmin Ara Begum; Syed M Akramuzzaman; Abu S G Faruque; Edward T Ryan; Firdausi Qadri; Stephen B Calderwood
Journal:  J Infect Dis       Date:  2004-05-25       Impact factor: 5.226

6.  5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial.

Authors:  Sujit K Bhattacharya; Dipika Sur; Mohammad Ali; Suman Kanungo; Young Ae You; Byomkesh Manna; Binod Sah; Swapan K Niyogi; Jin Kyung Park; Banwarilal Sarkar; Mahesh K Puri; Deok Ryun Kim; Jacqueline L Deen; Jan Holmgren; Rodney Carbis; Mandeep Singh Dhingra; Allan Donner; G Balakrish Nair; Anna Lena Lopez; Thomas F Wierzba; John D Clemens
Journal:  Lancet Infect Dis       Date:  2013-10-18       Impact factor: 25.071

7.  Vaccine poliovirus shedding and immune response to oral polio vaccine in HIV-infected and -uninfected Zimbabwean infants.

Authors:  Stephanie B Troy; Georgina Musingwini; Meira S Halpern; Chunhong Huang; Lynda Stranix-Chibanda; Diana Kouiavskaia; Avinash K Shetty; Konstantin Chumakov; Kusum Nathoo; Yvonne A Maldonado
Journal:  J Infect Dis       Date:  2013-05-09       Impact factor: 5.226

8.  Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti.

Authors:  Richelle C Charles; Isabelle J Hilaire; Leslie M Mayo-Smith; Jessica E Teng; J Gregory Jerome; Molly F Franke; Amit Saha; Yanan Yu; Paul Kováč; Stephen B Calderwood; Edward T Ryan; Regina C LaRocque; Charles P Almazor; Firdausi Qadri; Louise C Ivers; Jason B Harris
Journal:  PLoS Negl Trop Dis       Date:  2014-05-01

9.  Predictors of disease severity in patients admitted to a cholera treatment center in urban Haiti.

Authors:  Claude-Lyne Valcin; Karine Severe; Claudia T Riche; Benedict S Anglade; Colette Guiteau Moise; Michael Woodworth; Macarthur Charles; Zhongze Li; Patrice Joseph; Jean W Pape; Peter F Wright
Journal:  Am J Trop Med Hyg       Date:  2013-10       Impact factor: 2.345

10.  Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in HIV-infected and -uninfected children in south africa: a matched case-control study.

Authors:  Cheryl Cohen; Claire von Mollendorf; Linda de Gouveia; Nireshni Naidoo; Susan Meiring; Vanessa Quan; Vusi Nokeri; Melony Fortuin-de Smit; Babatyi Malope-Kgokong; David Moore; Gary Reubenson; Mamokgethi Moshe; Shabir A Madhi; Brian Eley; Ute Hallbauer; Ranmini Kularatne; Laura Conklin; Katherine L O'Brien; Elizabeth R Zell; Keith Klugman; Cynthia G Whitney; Anne von Gottberg
Journal:  Clin Infect Dis       Date:  2014-06-09       Impact factor: 9.079
View more
  10 in total

1.  Conjugate Vaccines from Bacterial Antigens by Squaric Acid Chemistry: A Closer Look.

Authors:  Peng Xu; Meagan Kelly; Willie F Vann; Firdausi Qadri; Edward T Ryan; Pavol Kováč
Journal:  Chembiochem       Date:  2017-03-23       Impact factor: 3.164

2.  Eliminating Cholera Transmission in Haiti.

Authors:  Louise C Ivers
Journal:  N Engl J Med       Date:  2016-12-07       Impact factor: 91.245

Review 3.  Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era.

Authors:  Sachin N Desai; Lorenzo Pezzoli; Kathryn P Alberti; Stephen Martin; Alejandro Costa; William Perea; Dominique Legros
Journal:  Hum Vaccin Immunother       Date:  2017-03-04       Impact factor: 3.452

4.  Antibody Secreting Cell Responses following Vaccination with Bivalent Oral Cholera Vaccine among Haitian Adults.

Authors:  Wilfredo R Matias; Brie Falkard; Richelle C Charles; Leslie M Mayo-Smith; Jessica E Teng; Peng Xu; Pavol Kováč; Edward T Ryan; Firdausi Qadri; Molly F Franke; Louise C Ivers; Jason B Harris
Journal:  PLoS Negl Trop Dis       Date:  2016-06-16

Review 5.  Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part II.

Authors:  Nancy F Crum-Cianflone; Eva Sullivan
Journal:  Infect Dis Ther       Date:  2017-08-05

6.  Correlates of Protection for Cholera.

Authors:  Anita S Iyer; Jason B Harris
Journal:  J Infect Dis       Date:  2021-12-20       Impact factor: 7.759

7.  Effect of HIV status and retinol on immunogenicity to oral cholera vaccine in adult population living in an endemic area of Lukanga Swamps, Zambia.

Authors:  Charlie Chaluma Luchen; John Mwaba; Harriet Ng'ombe; Peter Ibukun Oluwa Alabi; Michelo Simuyandi; Obvious N Chilyabanyama; Luiza Miyanda Hatyoka; Cynthia Mubanga; Samuel Bosomprah; Roma Chilengi; Cleopatra Caroline Chisenga
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

8.  The First Use of the Global Oral Cholera Vaccine Emergency Stockpile: Lessons from South Sudan.

Authors:  Abdinasir Abubakar; Andrew S Azman; John Rumunu; Iza Ciglenecki; Trina Helderman; Haley West; Justin Lessler; David A Sack; Stephen Martin; William Perea; Dominique Legros; Francisco J Luquero
Journal:  PLoS Med       Date:  2015-11-17       Impact factor: 11.069

9.  Cholera: Immunity and Prospects in Vaccine Development.

Authors:  Jason B Harris
Journal:  J Infect Dis       Date:  2018-10-15       Impact factor: 5.226

10.  A dysbiotic gut microbiome suppresses antibody mediated-protection against Vibrio cholerae.

Authors:  John C Macbeth; Rui Liu; Salma Alavi; Ansel Hsiao
Journal:  iScience       Date:  2021-11-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.